Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS
Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Anavex Life Sciences Presents Proof of Concept Controlled Phase 2 Clinical Trial Data
Follow us on social media
